DOCSLIB.ORG

Pfizer Consumer Healthcare

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pfizer Consumer Healthcare SafeSafe HarborHarbor StatementStatement ThisThis presspress releaserelease containscontains "forward"forward-looking-looking statements"statements" asas defineddefined inin thethe PrivatePrivate SecuritiesSecurities LitigationLitigation ReformReform ActAct ofof 1995.1995. TheseThese statementsstatements areare basedbased onon currentcurrent expectationsexpectations ofof futurefuture events.events. IfIf underlyingunderlying assumptionsassumptions proveprove inaccurateinaccurate oror unknownunknown risksrisks oror uncertaintiesuncertainties materialize,materialize, actualactual resultsresults couldcould varyvary materiallymaterially fromfrom JohnsonJohnson && Johnson'sJohnson's expectationsexpectations andand projections.projections. RisksRisks andand uncertaintiesuncertainties includeinclude generalgeneral industryindustry conditionsconditions andand competition;competition; economiceconomic conditions,conditions, suchsuch asas interestinterest raterate andand currencycurrency exchangeexchange raterate fluctuations;fluctuations; technologicaltechnological advancesadvances andand patentspatents attainedattained byby competitors;competitors; challengeschallenges inherentinherent inin newnew productproduct dedevelopment,velopment, includingincluding obtainingobtaining regulatoryregulatory approvals;approvals; domesticdomestic andand foreignforeign healthhealth carecare reformsreforms andand governmentalgovernmental lawslaws andand regulations;regulations; andand trendstrends towardtoward healthhealth carecare costcost containment.containment. AA furtherfurther listlist andand descriptiondescription ofof thesethese risks,risks, uncertaintiesuncertainties andand otherother factorsfactors cancan bebe foundfound inin ExhibitExhibit 9999 ofof thethe Company'sCompany's AnnualAnnual ReportReport onon FormForm 10-K10-K forfor thethe fiscalfiscal yearyear endedended DecemberDecember 30,30, 2007.2007. CopiesCopies ofof thisthis FormForm 10-K,10-K, asas wellwell asas subsequentsubsequent filings,filings, areare availableavailable ononlineline atat www.sec.gov,www.sec.gov, www.jnj.comwww.jnj.com oror onon requestrequest fromfrom JohnsonJohnson && Johnson.Johnson. JohnsonJohnson && JohnsonJohnson doesdoes notnot undertakeundertake toto updateupdate anyany forward-lookingforward-looking statementsstatements asas aa resultresult ofof newnew informationinformation oror futurefuture eventsevents oror developments.developments. ContentContent OverviewOverview •• OperatingOperating ModelModel •• HistoricalHistorical PerformancePerformance •• SegmentSegment OverviewOverview •• ThirdThird QuarterQuarter 20082008 ResultsResults ••Summar Summaryy STRATEGICSTRATEGIC PRINCIPLESPRINCIPLES OperatingOperating ModelModel •• BroadlyBroadly BasedBased inin HumanHuman HealthHealth CareCare •• ManagedManaged forfor thethe LongLong TermTerm •• DecentralizedDecentralized ManagementManagement ApproachApproach •• PeoplePeople andand ValuesValues BroadlyBroadly BasedBased-- World’sWorld’s MostMost ComprehensiveComprehensive HealthHealth CareCare CompanyCompany •• 20072007 SalesSales ofof $61.1$61.1 BillionBillion •• OverOver 250250 operatingoperating companiescompanies worldwideworldwide •• LeadershipLeadership positionspositions inin ethicalethical andand OTCOTC pharmaceuticals,pharmaceuticals, medical/surgicalmedical/surgical products,products, diagnosticsdiagnostics andand aa varietyvariety ofof consumerconsumer productsproducts BroadlyBroadly BasedBased –– AA StrategicStrategic AdvantageAdvantage 20072007 SegmentSegment OperatingOperating Profit*Profit* $15.9B $14.6B $6.0 % to Sales $5.7 2006 25.7% 2007 26.0% $7.6 $6.9 $2.0 $2.3 2006 2007 Consumer Pharm MD&D *Proforma including net impact of PCH; Refer to 3.2.07 8K filing for 2006 PCH impact to operating profit; Excludes IPR&D and other special items BroadlyBroadly BasedBased –– AA StrategicStrategic AdvantageAdvantage •• RapidlyRapidly capitalizecapitalize onon attractiveattractive opportunitiesopportunities •• KnowledgeKnowledge andand capabilitycapability transfertransfer •• DevelopmentDevelopment ofof convergingconverging technologiestechnologies •• AcceleratingAccelerating growthgrowth throughthrough geographicgeographic breadthbreadth •• LeveragingLeveraging scalescale OperatingOperating ModelModel •• BroadlyBroadly BasedBased inin HumanHuman HealthHealth CareCare •• ManagedManaged forfor thethe LongLong TermTerm •• DecentralizedDecentralized ManagementManagement ApproachApproach •• PeoplePeople andand ValuesValues LeadershipLeadership inin MajorMajor MarketsMarkets JohnsonJohnson && JohnsonJohnson #1#1 oror #2*#2* Anti-AnemiaAnti-Anemia Lo-CalLo-Cal SweetenersSweeteners AntipsychoticsAntipsychotics BloodBlood GlucoseGlucose MonitoringMonitoring Anti-TNFAnti-TNF BloodBlood ScreeningScreening && TypingTyping HormonalHormonal ContraceptivesContraceptives ElectrophysiologyElectrophysiology diagnosticsdiagnostics andand QuinoloneQuinolone Anti-InfectiveAnti-Infective catheterscatheters CoronaryCoronary StentsStents DisposableDisposable ContactContact LensesLenses MinimallyMinimally InvasiveInvasive SurgerySurgery OTCOTC PharmaceuticalsPharmaceuticals OrthopaedicsOrthopaedics SanitarySanitary ProtectionProtection SuturesSutures WoundWound CareCare BabyBaby && KidsKids CareCare *As of Dec 2007 GrowthGrowth StrategiesStrategies •• OrganicOrganic growthgrowth –– StrongStrong internalinternal R&DR&D capabilitycapability –– NurtureNurture newnew businesses;businesses; PrunePrune wherewhere appropriateappropriate •• StrategicStrategic partneringpartnering andand licensinglicensing •• SelectiveSelective acquisitionsacquisitions –– EnhanceEnhance existingexisting businessbusiness –– NewNew platformplatform forfor growthgrowth 19971997––20072007 TotalTotal ResearchResearch ExpenseExpense $U.S.$U.S. BillionsBillions $7.7 $2.4 1997 2007 10.6% Percent to Sales 12.6% The company has adopted SFAS No. 123(R) Shared Based Payment, applying the modified retrospective transition method. 1997-2005 reported financial statements have been restated accordingly. PartnerPartner ofof ChoiceChoice •• OverOver 100100 newnew thirdthird partyparty relationshipsrelationships annuallyannually •• InIn househouse ventureventure capitalcapital (JJDC)(JJDC) –– OverOver $475$475 millionmillion investedinvested asas ofof 20072007 inin aa broadbroad arrayarray ofof companiescompanies •• FocusFocus onon earlyearly stagestage productproduct developmentdevelopment MergersMergers && AcquisitionsAcquisitions –– RecentRecent ExamplesExamples StrategicStrategic movesmoves toto enhanceenhance ourour growthgrowth raterate andand createcreate long-termlong-term valuevalue forfor ourour shareholdersshareholders TypicallyTypically modestmodest inin size:size: overover 6060 inin thethe lastlast decadedecade •• BeijingBeijing DabaoDabao CosmeticsCosmetics Co.,Co., LtdLtd (7/08)(7/08) –– JohnsonJohnson && JohnsonJohnson (China)(China) InvestmentInvestment Co.Co. Ltd.Ltd. acquiredacquired BeijiBeijingng DabaoDabao CosmeticsCosmetics Company,Company, Ltd,Ltd, aa personalpersonal carecare companycompany withwith ChChina’sina’s ## 11 brandbrand moisturizer.moisturizer. •• ÅÅmicmic (6/08)(6/08) -- aa privatelyprivately heldheld SwedishSwedish developerdeveloper ofof inin vitrovitro diagnosticdiagnostic (IVD)(IVD) technologiestechnologies forfor useuse inin Point-of-CarPoint-of-Caree (POC)(POC) andand near-patientnear-patient settingssettings •• Disc-O-TechDisc-O-Tech MedicalMedical Technologies,Technologies, Ltd.Ltd. (12/07)(12/07) -- AcquisitionAcquisition ofof certaincertain assets,assets, includingincluding intellectualintellectual propertyproperty rights,rights, relatedrelated toto thethe treatmenttreatment ofof vertebralvertebral compressioncompression fracturesfractures fromfrom Disco-o-TechDisco-o-Tech MeMedicaldical Technologies,Technologies, aa privatelyprivately heldheld company,company, andand itsits subsidiarysubsidiary •• EnsureEnsure Medical,Medical, Inc.Inc. (7/06)(7/06) -- AcquisitionAcquisition ofof EnsureEnsure Medical,Medical, aa privatelyprivately heldheld companycompany willwill provideprovide CordisCordis withwith aa develdevelopmentopment stagestage femoralfemoral arteryartery closureclosure devicedevice (ACD)(ACD) andand relatedrelated IPIP andand know-howknow-how •• ColBarColBar LifeScienceLifeScience Ltd.Ltd. (7/06)(7/06) -- AcquisitionAcquisition ofof ColBarColBar LifeScience,LifeScience, anan IsraeliIsraeli ventured-backed,ventured-backed, privatelyprivately heldheld medicalmedical devicedevice companycompany withwith expertiseexpertise inin collagen-basedcollagen-based productsproducts MergersMergers && AcquisitionsAcquisitions –– RecentRecent ExamplesExamples •• VascularVascular ControlControl SystemsSystems (5/06)(5/06) -- AcquiredAcquired aa ventureventure fundedfunded privatelyprivately heldheld companycompany thatthat developeddeveloped technologytechnology thatthat willwill bebe usedused forfor thethe treatmenttreatment ofof fibroidsfibroids andand dysfunctionaldysfunctional uterineuterine bleedingbleeding •• GroupeGroupe VendomeVendome SASA (5/06)(5/06) -- JohnsonJohnson && JohnsonJohnson ConsumerConsumer FranceFrance SASSAS acquiredacquired GroupeGroupe Vendome,Vendome, aa privatelprivatelyy heldheld FrenchFrench marketermarketer ofof adultadult andand babybaby skinskin carecare productsproducts •• FutureFuture MedicalMedical SystemsSystems GroupGroup NVNV (FMS)(FMS) (3/06)(3/06) -- TheThe acquisitionacquisition ofof FMS,FMS, willwill allowallow DePuyDePuy MitekMitek toto enteenterr thethe fluidfluid managementmanagement andand
Load more

Recommended publications
  • 2019 Health for Humanity Report
    2019 Health for Humanity Report Progress in Sustainability Report Summary Contents Message from Our Chairman and CEO 3 Sustainability Approach 4 2019 Year in Brief 5 Better Health for All: Tackling the World’s 6 Toughest Health Challenges Better Health for All: Access, Community 7 Health & Innovation Responsible Business Practices 8 Environmental Health 9 UNICEF, the Government of Vietnam and Johnson & Johnson are partnering on a national program to train more than 500 ethnic minority midwives in remote regions to provide effective maternal and child health interventions including early essential newborn care in village clinics and homes. Photo by Paul Bettings Front cover Volunteers, frontline health workers and government officials at the launch of the Umurinzi vaccination program in Rwanda. In October 2019, Johnson & Johnson committed to donating up to 700,000 regimens of Janssen’s investigational Ebola vaccine to support the Ebola outbreak response in Rwanda and the Democratic Republic of the Congo. Photos by Rwanda Ministry of Health 2019 Health2017 for Health Humanity for HumanityReport Summary Report 33 Message from Our Chairman and CEO Dear Johnson & Johnson Stakeholders, We know this mission will always be unfinished, and affirmed unequivocally that there is a fundamental that we will occasionally fall short. But that only serves connection between serving all stakeholders and 2019 was a year of profound change and great contrasts as motivation to move faster than we’ve ever moved generating sustainable, long-term value. around the globe. before in making bigger strides toward some of our most ambitious goals. And as we’ve detailed in this Report, we The demands for global healthcare and responsible We saw unprecedented innovation and encouraging have plenty of positive momentum worth recognizing.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Frequently Asked Questions
    Frequently Asked Questions Why are these companies included on the "Do Test" list? The following companies manufacture products that are tested on animals at some stage of development. Those marked with a Ƈ are currently observing a moratorium on (i.e., current suspension of) animal testing. Please encourage them to announce a permanent ban. Listed in parentheses are examples of products manufactured by either the company listed or, if applicable, its parent company. For a complete listing of products manufactured by a company on this list, please visit the company's website or contact the company directly for more information. Companies on this list may manufacture individual lines of products that have not been tested on animals. They have not, however, eliminated tests on animals for their entire line of cosmetics and household products. What if a company isn't on either of PETA's lists? Some companies have refused to respond to specific questions about their testing practices. It appears likely that these companies do test on animals at some stage of product development, and their refusal to clarify their testing policies appears to be an attempt to mislead consumers. Other companies may be new. If you find a company not included on our lists, please share the company's contact information with PETA so that we can contact the company directly. Legend Ƈ The company is currently observing a moratorium on animal testing. 3M 3M Corporate 1-888-364-3577 www.solutions.3m.com Headquarters 3M Center St. Paul, Minnesota 55144-1000 Acuvue (Johnson & Johnson) Customer (800) 843-2020 www.acuvue.com/ Relations, D-QA 7500 Centurion Parkway Jacksonville, Florida 32256 Aim (Church & Dwight) P.O.
    [Show full text]
  • Diabetes Close up December Supplement, 2005, No. 53 J&J To
    Diabetes Close Up December supplement, 2005, No. 53 J&J To Buy Animas in Sublime Strategic Play T h e S h o r t e r V e r s i o n From the Editor: J&J’s LifeScan announced December 16 that it intends to buy Animas Corporation for $518 million in cash, or $24.50/share, a 35% premium over Animas’ closing price the 15th. We think this acquisition makes very good strategic sense – essentially, it’s the #1 glucose monitoring company buying the #2 pump player. In many respects, this was a classic J&J deal – Animas is newly profitable this year, the deal is immediately accretive, and it offers J&J an excellent leg up as it enters the pump market. Too, J&J had owned ~10% of Animas for some time. Now, while Animas is #2, it is still far behind leader Medtronic MiniMed, whose new(ish) leader, successful cardiac surgery veteran Bob Guezuraga has really impressed the diabetes community. Smart, ambitious, and seemingly hyper-focused, he appears very serious about taking the business to the next level and leaving success in diabetes as his legacy. What could be better for patients than significant focus industry-wide on better physiologic delivery? As competition heightens, we expect innovation to move faster – all good, from a patient perspective. Details on the acquisition are below – what J&J gets, what Animas gets, and what’s next. What a way to end what’s been a very dynamic year in diabetes … --Kelly L. Close DCU #53, December supplement 2005, J&J Buys Animas in Sublimely Strategic Deal.
    [Show full text]
  • Creative Director 561.714.1585 Andy Mathurin
    Hello, I am: Looking for role as: Let’s Connect: Andy Mathurin Creative Director 561.714.1585 Associate Creative Director, [email protected] Brand Strategist New York What I do: PROFILE Brand Strategy Over 8 years leading branding and marketing concepts with career spanning 360 campaigns, broadcast, print, OOH, social, digital, video and experiential Identity Design across major worldwide brands. Energetic and a creative visionary offering Storytelling demonstrated expertise in all aspects of branding and strategy, with core focus Thought Leader on delivering business results. Team Builder Marketing WINS Project Management Successes have included winning several accounts for new business, resulting in agency being awarded Global Agency of the Year by AdAge & Adweek. Toolkit: AOR: Havas - Vascepa 2019, Havas - Alcon 2019, J3 - OGX 2018, UM - H&M 2017, UM - Sony 2017, BMW 2016, UM - Coca Cola 2016 Sketch XD Microsoft Office PROFESSIONAL EXPERIENCE Avocode 03.18 HAVAS | Manhattan, NY Photoshop Present Associate Creative Director Strategic partner, focusing on brand equity for healthcare and InDesign pharmaceutical brands. Responsible for new business and leading creative Illustration team/studio across all digital platforms (specializing in social). After Effects Brands include: Zicam, Alcon, GSK, NUCALA, TRELEGY, & ANORO. 09.14 Universal McCann Worldwide | Manhattan, NY 03.18 Personality: Associate Creative Director + Senior Art Director Hands-on leader in identity design. Champion participant in winning new Human business pitches. Guiding and advising clients on high-level executions. Confident Brands include: Sony Pictures, GoPro, McCormick, BMW... and more. Effective Communicator - Demonstrate strong leadership overseeing staff in the day-to-day projects Motivational Honest with Integrity - Deliver against demanding brand objectives and develop creative that Empathetic exceeds business needs, managing projects from concept through completion: timelines, budgets, schedules, etc.
    [Show full text]
  • Ethics and Social Responsibility
    Fundamentals of Business, Second Edition Chapter 4 Ethics and Social Responsibility Content for this chapter was adapted from the Saylor Foundation’s http://www.saylor.org/site/textbooks/Exploring%20Business.docx by Virginia Tech under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License. The Saylor Foundation previously adapted this work under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License without attribution as requested by the work’s original creator or licensee. If you redistribute any part of this work, you must retain on every digital or print page view the following attribution: Download this book for free at: http://hdl.handle.net/10919/84848 Lead: Stephen J. Skripak Contributors: Anastasia Cortes, Gary Walton, Anita Walz Digital and Print Production: Corinne Guimont with Robert Browder Alternative Text and Accessibility: Stephanie Edwards, Christa Miller, and Corinne Guimont Selected graphics: Brian Craig Cover design: Trevor Finney Student Reviewers: Jonathan De Pena, Nina Lindsay, Sachi Soni Project Manager/Editor: Anita Walz This chapter is licensed with a Creative Commons Attribution-Noncommercial-Sharealike 3.0 License. Download this book for free at: http://hdl.handle.net/10919/84848 VT Publishing, a division of the University Libraries at Virginia Tech August 2018 4. Chapter 4 Ethics and Social Responsibility Learning Objectives 1. Define business ethics and explain what it means to act ethically in business. 2. Explain why we study business ethics. 3. Identify ethical issues that you might face in business, such as insider trading, conflicts of interest, and bribery, and explain rationalizations for unethical behavior. 4. Identify steps you can take to maintain your honesty and integrity in a business environment.
    [Show full text]
  • Lna 2006 Profiles J.Qxp
    1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp.
    [Show full text]
  • Lifescan Ethicon
    LouiseLouise MehrotraMehrotra ViceVice PresidentPresident InvestorInvestor RelationsRelations ““SafeSafe HarborHarbor”” StatementStatement This presentation may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments. WilliamWilliam C.C. WeldonWeldon ChairmanChairman ofof thethe BoardBoard && ChiefChief ExecutiveExecutive OfficerOfficer TodayToday’’ss AgendaAgenda
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • Open PDF File, 175.47 KB, for Top 100 Covered Recipients, Non Hospital
    Top 100 Covered Recipients, Non Hospital, Detail Rank Recipient City State License License Covered Manufacturer Manufacturer Payment Number Total Fullname Type Number Recipient Name ID Categories of Payment ID Events QUADRANT HEALTH BEVERLY MA Clinical 22D2063293 357395 Novartis CC0243 Other 61 $2,251,831.00 STRATEGIES INC Laboratory Pharmaceuticals 1 Total for Covered Recipient : QUADRANT HEALTH STRATEGIES INC $2,251,831.00 BOSTON BOSTON MA Clinical 22D0996308 241308 Celgene CC0109 Grants/ 2 $30,000.00 UNIVERSITY Laboratory Corporation Educational SCHOOL OF Gifts MEDICINE Csl Behring Llc CC0101 Education/ 2 $5,000.00 Training Depuy CC0135 CMEs, third- 2 $26,000.00 Orthopaedics, Inc., party Conferences, or Meetings Other 1 $7,500.00 Dr. Reddy's CC0592 Grants/ 2 $121,820.00 Laboratories, Inc Educational Gifts Janssen Biotech, CC0194 Grants/ 2 $105,000.00 Inc. Educational Gifts Other 1 $1,500.00 Janssen CC0535 CMEs, third- 2 $175,000.00 Pharmaceuticals, party Inc. Conferences, or Meetings Novo Nordisk Inc. CC0006 Grants/ 2 $136,436.00 Educational Gifts Smith & Nephew, CC0402 CMEs, third- 1 $1,000.00 Inc. party Conferences, or Meetings Stryker Corporation CC0290 CMEs, third- 1 $1,000.00 party Conferences, or Meetings Takeda CC0300 CMEs, third- 2 $60,218.00 Pharmaceuticals party Aug 1, 2016 1 8:44:29 AM Top 100 Covered Recipients, Non Hospital, Detail Rank Recipient City State License License Covered Manufacturer Manufacturer Payment Number Total Fullname Type Number Recipient Name ID Categories of Payment ID Events BOSTON BOSTON MA Clinical 22D0996308 241308 America, Inc CC0300 Conferences, or UNIVERSITY Laboratory Meetings SCHOOL OF Grants/ 3 $800,000.00 MEDICINE Educational Gifts Valeant CC0346 CMEs, third- 2 $5,000.00 Pharmaceuticals party North America Conferences, or Meetings W.L.
    [Show full text]
  • Palm Oil Shopping Guide: Current Best Choices
    FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of Make a Difference RSPO Members RSPO Members RSPO Members RSPO Members RSPO Members for Wild 3 Musketeers Cinnamon Toast Crunch Honey Maid Grahams Mothers Cookies Splenda Orangutans Act II Coffee Mate Hot Pockets Mountain High Yogurt Starburst Adam's PB Country Crock Hungry Jack Muffin Mam Pastries Stouffers Almond Joy Country Time Hunt's Muir Glen Trident Gum BOYCOTTING PALM Altoids Crisco International Delight Nabisco Sun Chips OIL IS NOT THE Arnott's Biscuits Crunch and Munch Jenny Craig Meals Nature Valley SuperMoist Cake Mixes SOLUTION… Aunt Jemima Foods Dean's Dips Jeno's Pizza Near East Sweet Rewards Bars Austin Brand Crackers Doritos Jif PB Nerds Sweet Tarts Supporting Baby Ruth Dove Chocolates Jiffy Pop Nesquik Swiss Miss companies that are Bac Os Dreyer's Jolly Ranchers Nestle Products Tombstone Pizza members of the Baker's Chocolate Edy's Justin's NutButter Nutter Butter Cookies Tostitos RSPO (Roundtable on Balance Bars Egg Beaters Justin's PB Cups Old El Paso Total Cereal Sustainable Palm Oil) Banquet Meals Endangered Species Choc. Keebler Cookies Oreo Cookies Totino's Pizza is the most Barilla Famous Amos Cookies Keebler Crackers Orville Redenbacher's Trix Cereal responsible solution. BelVita Fiber One Products Kellogg's Products Pam Tuna Helper Ben & Jerry's Ice Cream Fleischmann's Kid Cuisine Parent's Choice Twix Bertolli Frito Lay Kit Kat Parkay Twizzlers For more information Betty Crocker products Folgers Kix Cereal Pasta
    [Show full text]